Head-to-head · free
LB Pharmaceuticals vs Medtronic Plc
LBRX vs MDT — return on capital, cash generation, margins and balance sheet side by side.
LBRX
0 / 3
measures where LBRX leads
MDT
3 / 3
measures where MDT leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | LBRX · FY2025 | MDT · FY2026 |
|---|---|---|
| Revenue | — | $36.4B |
| Net income | (25.2M) | $4.8B |
| Revenue growth (yearly, multi-year) | — | 3.5% |
| Free cash flow | (35.3M) | $5.4B |
| Free cash flow margin | — | 14.9% |
| Net cash / (debt) | — | — |
| ROIC | — | 6.5% |
| Return on equity | — | 9.8% |
| Gross margin | — | 65.0% |
| Operating margin | — | 18.8% |
| Net debt / EBITDA | 8.32x | 2.75x |
Figures are as reported by each company; latest fiscal year shown.
Where LB Pharmaceuticals's cash went (FY2025)
- Capital spending
- $52000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Medtronic Plc's cash went (FY2026)
- Capital spending
- $1.9B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free